Reviva Pharmaceuticals Holdings Inc. announced that European Patent 3749324 has been granted by the European Patent Office, covering the use of brilaroxazine for the treatment of pulmonary fibrosis, including idiopathic pulmonary fibrosis (IPF). Similar patents have also been granted in the United States, China, and Japan. Brilaroxazine, which has received Orphan Drug Designation from the U.S. FDA for IPF, is highlighted for its novel mechanism of action targeting serotonin signaling implicated in pulmonary fibrosis. The company stated that this new patent further strengthens its intellectual property portfolio and supports continued development of brilaroxazine for chronic fibrotic disorders.